Aldeyra Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $40.12M
- P/E (TTM)
- –
- Dividend yield
- –
About Aldeyra Therapeutics
Pharmaceutical Preparations, SIC 2834
Aldeyra Therapeutics, Inc. is a biotechnology company focused on developing therapies for immune-mediated diseases. Its approach centers on modulating protein systems through small molecules designed to bind, degrade, and deplete reactive aldehyde species (RASP), targeting multiple inflammatory pathways simultaneously. The company’s pipeline includes late-stage investigational candidates such as reproxalap, an ophthalmic solution evaluated for dry eye disease and allergic conjunctivitis, and ADX-2191, an intravitreal methotrexate formulation for primary vitreoretinal lymphoma and retinitis pigmentosa. In addition, it develops product candidates like ADX-248 and ADX-246 for systemic, dermatologic, and retinal conditions.
The company operates in the United States and has an option agreement with AbbVie to collaborate on the development and commercialization of reproxalap. Aldeyra conducts preclinical research, animal studies, and clinical trials for its therapeutic candidates. It maintains its principal executive offices in Lexington, Massachusetts.
Summary of the business section of Aldeyra Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Aldeyra Therapeutics, Inc.
- Headquarters
- Concord, MA
- Address
- 23 Bradford Street, Suite 1 01742
- Phone
- (781) 761-4904
- Website
- aldeyra.com
- Employees
- 8, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- BDO USA, P.C., Boston, Massachusetts
Stock & identifiers
- Ticker
- ALDX
- Exchange
- Nasdaq
- IPO date
- May 2, 2014
- Shares outstanding
- 60M, Aug 4, 2026
- Public float
- $231.90M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- SEC CIK
- 1341235
- CUSIP
- 01438T106
- ISIN
- US01438T1060
- LEI
- 529900HGKY864E4Y9014
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Todd C. Brady | President and CEO, Director | 1,721,298 |
| Michael Alfieri | Principal Financial Officer | 7,500 |
| Stephen Machatha | Chief Development Officer | 222,010 |
| Richard Douglas | Director | 195,000 |
| Neal Walker | Director | 15,854 |
| Gary M. Phillips | Director | 14,812 |
| William D. Clark | Director | – |
| Ben Bronstein | Director | 28,248 |
| Darlene M. Deptula-Hicks | Director | – |
| Nancy Miller-Rich | Director | 922 |
| Martin Joseph Joyce | Director | 23,967 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Todd C. Brady, M.D., Ph.D | $4.70M | $4.29M | $848.17K | $74 | – |
| FY2024 Todd C. Brady, M.D., Ph.D | $3.93M | $6.05M | $1.01M | $72 | – |
| FY2023 Todd C. Brady, M.D., Ph.D | $3.68M | -$1.22M | $1.28M | $50 | – |
| FY2022 Todd C. Brady, M.D., Ph.D | $2.86M | $10.61M | $2.02M | $174 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 8 full-time employees and had engaged a number of consultants.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jan 29, 2019 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| May 2, 2014 | IPO | Initial public offering priced (424B4 prospectus) |
| Mar 4, 2014 | Listing | Registration of securities on an exchange (Form 8-A) |
| Mar 4, 2014 | Name change | Name changed from Aldexa Therapeutics, Inc. to Aldeyra Therapeutics, Inc. |
| Aug 1, 2008 | Name change | Name changed from Neuron Systems Inc to Aldexa Therapeutics, Inc. |